Vaikuttaa mielenkiintoiselta Faronin osuminen tällaisen jenkkitalon tutkaan, kun kyse ei ilmeisestikään ole maksetusta analyysistä? Stifelin AUM näyttäisi olevan n. 500 miljardia taalaa, jolla asettuu Euroopasta katsottuna Nordean ja Deutche Bankin välimaastoon. Toimistot löytyy kaikilta tärkeiltä markkinoilta tällä puolella rapakkoa, mutta Helsingin kohdalla näyttää tyhjää…
Netistä löytyy Stifelin ihan vapaasti luettavissa oleva biopharma-sektoria koskeva rapsa toukokuulta, josta poimin etenkin tämän kohdan:
M&A Seems Highly Likely to Pick Up
Meanwhile, deal valuations are being carefully weighed against rising
interest rates, political uncertainties and fluctuating capital markets.
Pharma buyers are focusing on assets with near-term revenue potential or
those with clear paths to regulatory approval. Even in smaller deals,
diligence around reimbursement potential, manufacturing scalability, and
competitive market positioning has intensified compared to pre-pandemic
years.
Despite recent tariff and environmental challenges, we believe that biotech
> M&A will gain momentum in 2025. Large pharmaceutical companies face
> steep patent cliffs over the next five years and need to backfill their
> pipelines to offset revenue losses. As a result, we expect a steady stream of
> small-to-mid-sized acquisitions targeting phase 2, phase 3 and commercial
> assets that can generate revenue within the next 3–5 years, rather than
> early-stage platform technologies and emerging drug candidates.
We would note that pharma M&A in 2025 is largely characterized in today’s
market by strategic precision rather than scale. Deals are being shaped by
regulatory caution, therapeutic needs, manufacturing priorities and the
urgent need for commercial-ready assets, all within a volatile political and
economic backdrop. While the megadeals of the past decade are less likely
in the near term, a steady cadence of targeted acquisitions such as last
week’s Regulus deal is positioning big pharma to weather industry
challenges and prepare for future growth.
Koko rapsa löytyy täältä: